总部位于纽约的BrainStorm Cell Therapeutics Inc.已实施了其普通股的反向拆股，这是为满足纳斯达克持续上市要求的战略举措。这家专注于为高度致残的神经退行性疾病开发创新自体细胞疗法的生物技术公司宣布，反向拆股比例为1:15，于周日东部时间晚上11:59生效。 这项公司行动于2024年9月30日向特拉华州州务卿提交，旨在提高公司普通股的每股投标价格，从而确保满足纳斯达克设定 ...

While brainstorming sessions are common in many workplaces, psychological and social mechanisms can undermine our creative ...

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a biotechnology company specializing in biological products, has announced a one-for-fifteen reverse stock split of its common stock. The board's ...

在充满挑战的市场环境中，Brainstorm Cell Therapeutics Inc. (BCLI)股票创下了新的52周低点，跌至1.97美元。这家专注于开发神经退行性疾病创新治疗方法的生物技术公司经历了艰难的一年，其股价反映出一年来-13.79%的变化。投资者正密切关注公司的进展和可能影响其股票表现的潜在催化剂，因为它正在经历一个生物技术板块波动性加剧和投资者谨慎的时期。 在其他近期新闻中， ...

The company is currently preparing for a Phase 3b clinical trial of NurOwn in patients with amyotrophic BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell ...

Each week, Quartz rounds up product launches, updates, and funding news from artificial intelligence-focused startups and ...

The new product provides additional flexibility and simplicity for virtual production and AR content creation, at a lower ...

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative ...

As companies expand the use of generative AI, the pay-off can range from increased productivity to higher revenues.

NEW YORK-based BrainStorm Cell Therapeutics Inc. has implemented a reverse stock split of its common stock in a strategic move to satisfy NASDAQ's continued listing requirements. The biotechnology ...

In a concerted effort to address the challenges facing the healthcare sector, key stakeholders in the health sector have ...